Eisai, Inc Hiring for Scientist II, Bioanalysis and DMPK job in Cambridge Full Time

At Eisai, satisfying unmet medical needs and increasing the benefits healthcare provides to patients, their families, and caregivers is Eisai’s human health care (hhc) mission. We’re a growing pharmaceutical company that is breaking through in neurology and oncology, with a strong emphasis on research and development. Our history includes the development of many innovative medicines, notably the discovery of the world’s most widely-used treatment for Alzheimer’s disease. As we continue to expand, we are seeking highly-motivated individuals who want to work in a fast-paced environment and make a difference. If this is your profile, we want to hear from you.

General Summary:

Eisai has been dedicated for decades to the pursuit of novel therapeutics to improve the lives of people suffering from dementia and their families. Recognizing the potential for human genetics, data sciences and precision chemistry to disrupt the drug discovery paradigm, Eisai launched the Eisai Center for Genetics Guided Dementia Discovery (G2D2) in 2019 to accelerate the discovery of innovative therapeutics. G2D2 is a unique drug discovery organization driven by a diverse group of passionate, dedicated and collaborative scientists committed to one goal: delivering breakthroughs for patients and their families. All Eisai employees, as part of the company’s human health care (hhc) mission, spend at least 1% of their working time with patients and families to ensure that the innovation we drive is based on an understanding of their real needs.

The predominant research focus at G2D2, driven by insights from human genetics, is immunodementia: targeting immune-related targets for dementia. At G2D2, we focus not only on how human genetics and other human biology data may identify and validate therapeutic targets with increased likelihood of success in clinical trials, but also how this data guides selection of the best approaches to design new therapeutics and the selection of strategies to deliver these therapeutics to the right patient at the right time. Recognizing the obvious alignment between human genetics and nucleic acid modalities, our precision chemistry strategy is to directly validate human biology hypotheses by utilizing our unique RNA targeting therapeutic platform. G2D2’s expertise in harnessing molecular complexity (stereochemistry and topology) to successfully discover and develop natural product based therapeutics has been applied to create an evolving unique nucleic acid immunotherapeutic platform that is being employed globally in multiple clinical and pre-clinical programs at Eisai.

G2D2’s cutting-edge 50,000-square-foot facility is strategically located in Cambridge, MA, to accelerate collaborations with leading research institutes in this world-class biotech hub. Our facility has been designed around an open-lab concept, enabling scientists with multi-disciplinary backgrounds to work together in a single integrated lab space. Our labs include state-of-the-art capabilities that support the variety of disciplines located at the site, including medicinal and process chemistry, in-vitro and in-vivo biology, microscopy, DMPK, drug safety, chemical and structural biology, automation and screening, and more. G2D2 is home to Eisai’s global capabilities in neurology discovery data science. G2D2 is also home to other global Eisai functions, including global health, DMPK, Safety, IP, oncology, thus providing a rich environment for cross-functional interaction. Our office is designed to foster an atmosphere of mission-driven and collaborative science, using new collaboration tools and technologies, and is being optimized to support a hybrid work environment.

At Eisai, we highly value both internal and external collaboration and pursue flexible research models with a range of external scientific partners to accelerate delivery of innovative medicines. To this end, the G2D2 facility includes the Eisai Innovation Center Biolabs, which provides space and infrastructure to start-up/spin-out companies conducting high-risk but potentially transformative research that can impact the discovery of breakthrough neuroscience therapeutics.

More information about G2D2 is provided here ( http://eisai.mediaroom.com/2018-06-12-Eisai-Inc-to-Launch-Center-for-Genetics-Guided-Dementia-Discovery-in-Cambridge-Massachusetts ) and here ( https://us.eisai.com/research/g2d2 ), and about Eisai’s Neurology strategy and pipeline are provided here ( https://www.eisai.com/index.html ).

Job Summary

The DMPK group at Eisai Center for Genetics guided Dementia discovery in Cambridge is seeking for a multi-disciplinary team-oriented Scientist with skillset emphasis in the area of quantitative bioanalysis and general ADME/DMPK. The major role of this position would be responsible for developing bioanalytical methods using LC-MS/MS, working together with other members at DMPK team, conducting in vitro ADME studies to support discovery projects. This role also has the potential to serve as DMPK functional lead in cross-functional projects. Additional duty will include workflow logistics, such as interaction with internal/external academic and CRO collaborators, track study status, review data and upload data into database.

Essential Functions

• Develop robust bioanalytical methods for in vitro ADME studies and in vivo study samples using LC-MS/MS. Operate and maintain instruments independently with adequate ability of troubleshooting.
• Conduct various in vitro ADME experiments, including but not limited to stability studies using microsomes, hepatocytes and/or tissue homogenate, cell-based permeability, and transporter assays.
• Analyze raw data and report deliverables including relevant parameters for in vitro ADME and in vivo PK assays in a timely fashion.
• Communicate research results to supervisor and project managers, process data, summarize in report format and upload into database in a timely manner.
• Maintain laboratory notebook and complete all documentation according to the standard operating procedures.
• Involve in comprehensive mechanistic ADME studies and author scientific manuscript for publication purpose as needed.
• Maintain smooth workflow with internal/external collaborators including track study status, review and audit data and upload data into database.
• Represent DMPK function on multidisciplinary project teams.
• Represent Eisai in external collaborations such as the IQ consortium.
• Contribute to regulatory filings such as IND, NDA.

Requirements

• Ph.D. in Biology, Chemistry, Pharmaceutical Sciences or other related field, with at least 2 years of’ pharmaceutical industry or post-doctoral experience.
• Hands on experience and knowledge with analytical techniques (UPLC/HPLC and Triple Quad/TOF Mass Spectrometry) are essential.
• Demonstrate method development and troubleshooting capability and independence for in vitro ADME assays executions.
• Mechanistic DMPK knowledge background is required
• Experience in non-compartmental PK analysis is a plus.
• DMPK project and CRO management experience is a plus.
• Familiar with standard data analysis software packages used in the industry such as Excel, GraphPad, Phoenix or other similar software packages.
• Familiar with electronic notebooks.
• Ideal candidate should be someone who is self-motivated, eager to explore and learn new skills, and is able to work productively in a team environment.
• Excellent written and oral communication skills.

#LI-JL1

#IND-123

Eisai is an equal opportunity employer and as such, is committed in policy and in practice to recruit, hire, train, and promote in all job qualifications without regard to race, color, religion, gender, age, national origin, citizenship status, marital status, sexual orientation, gender identity, disability or veteran status. Similarly, considering the need for reasonable accommodations, Eisai prohibits discrimination against persons because of disability, including disabled veterans.

Eisai Inc. participates in E-Verify. E-Verify is an Internet based system operated by the Department of Homeland Security in partnership with the Social Security Administration that allows participating employers to electronically verify the employment eligibility of all new hires in the United States. Please click on the following link for more information:

Right To Work
E-Verify Participation